1 | 1 | | 88R23304 CJD-F |
---|
2 | 2 | | By: Harris of Williamson H.B. No. 3351 |
---|
3 | 3 | | |
---|
4 | 4 | | |
---|
5 | 5 | | A BILL TO BE ENTITLED |
---|
6 | 6 | | AN ACT |
---|
7 | 7 | | relating to standards required for certain rankings of physicians |
---|
8 | 8 | | by health benefit plan issuers. |
---|
9 | 9 | | BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
---|
10 | 10 | | SECTION 1. Section 1460.003, Insurance Code, is amended by |
---|
11 | 11 | | amending Subsection (a) and adding Subsection (a-1) to read as |
---|
12 | 12 | | follows: |
---|
13 | 13 | | (a) A health benefit plan issuer, including a subsidiary or |
---|
14 | 14 | | affiliate, may not rank physicians or[,] classify physicians into |
---|
15 | 15 | | tiers based on performance[, or publish physician-specific |
---|
16 | 16 | | information that includes rankings, tiers, ratings, or other |
---|
17 | 17 | | comparisons of a physician's performance against standards, |
---|
18 | 18 | | measures, or other physicians,] unless: |
---|
19 | 19 | | (1) the standards used by the health benefit plan |
---|
20 | 20 | | issuer to rank or classify are propagated or developed by an |
---|
21 | 21 | | organization designated by the commissioner through rules adopted |
---|
22 | 22 | | under Section 1460.005; |
---|
23 | 23 | | (2) the ranking, comparison, or evaluation: |
---|
24 | 24 | | (A) is disclosed to each affected physician at |
---|
25 | 25 | | least 45 days before the date the ranking, comparison, or |
---|
26 | 26 | | evaluation is released, published, or distributed to enrollees by |
---|
27 | 27 | | the health benefit plan issuer; and |
---|
28 | 28 | | (B) identifies which products or networks |
---|
29 | 29 | | offered by the health benefit plan issuer the ranking, comparison, |
---|
30 | 30 | | or evaluation will be used for; and |
---|
31 | 31 | | (3) each affected physician is given an easy-to-use |
---|
32 | 32 | | process to identify discrepancies between the standards and the |
---|
33 | 33 | | ranking, comparison, or evaluation as propagated by the health |
---|
34 | 34 | | benefit plan issuer [the standards used by the health benefit plan |
---|
35 | 35 | | issuer conform to nationally recognized standards and guidelines as |
---|
36 | 36 | | required by rules adopted under Section 1460.005; |
---|
37 | 37 | | [(2) the standards and measurements to be used by the |
---|
38 | 38 | | health benefit plan issuer are disclosed to each affected physician |
---|
39 | 39 | | before any evaluation period used by the health benefit plan |
---|
40 | 40 | | issuer; and |
---|
41 | 41 | | [(3) each affected physician is afforded, before any |
---|
42 | 42 | | publication or other public dissemination, an opportunity to |
---|
43 | 43 | | dispute the ranking or classification through a process that, at a |
---|
44 | 44 | | minimum, includes due process protections that conform to the |
---|
45 | 45 | | following protections: |
---|
46 | 46 | | [(A) the health benefit plan issuer provides at |
---|
47 | 47 | | least 45 days' written notice to the physician of the proposed |
---|
48 | 48 | | rating, ranking, tiering, or comparison, including the |
---|
49 | 49 | | methodologies, data, and all other information utilized by the |
---|
50 | 50 | | health benefit plan issuer in its rating, tiering, ranking, or |
---|
51 | 51 | | comparison decision; |
---|
52 | 52 | | [(B) in addition to any written fair |
---|
53 | 53 | | reconsideration process, the health benefit plan issuer, upon a |
---|
54 | 54 | | request for review that is made within 30 days of receiving the |
---|
55 | 55 | | notice under Paragraph (A), provides a fair reconsideration |
---|
56 | 56 | | proceeding, at the physician's option: |
---|
57 | 57 | | [(i) by teleconference, at an agreed upon |
---|
58 | 58 | | time; or |
---|
59 | 59 | | [(ii) in person, at an agreed upon time or |
---|
60 | 60 | | between the hours of 8:00 a.m. and 5:00 p.m. Monday through Friday; |
---|
61 | 61 | | [(C) the physician has the right to provide |
---|
62 | 62 | | information at a requested fair reconsideration proceeding for |
---|
63 | 63 | | determination by a decision-maker, have a representative |
---|
64 | 64 | | participate in the fair reconsideration proceeding, and submit a |
---|
65 | 65 | | written statement at the conclusion of the fair reconsideration |
---|
66 | 66 | | proceeding; and |
---|
67 | 67 | | [(D) the health benefit plan issuer provides a |
---|
68 | 68 | | written communication of the outcome of a fair reconsideration |
---|
69 | 69 | | proceeding prior to any publication or dissemination of the rating, |
---|
70 | 70 | | ranking, tiering, or comparison. The written communication must |
---|
71 | 71 | | include the specific reasons for the final decision]. |
---|
72 | 72 | | (a-1) If a physician submits information to a health benefit |
---|
73 | 73 | | plan issuer under Subsection (a)(3) sufficient to establish a |
---|
74 | 74 | | discrepancy, the health benefit plan issuer must remedy the |
---|
75 | 75 | | discrepancy by the later of: |
---|
76 | 76 | | (1) publication; or |
---|
77 | 77 | | (2) the 30th day after the date the health benefit plan |
---|
78 | 78 | | issuer receives the information. |
---|
79 | 79 | | SECTION 2. Section 1460.005(c), Insurance Code, is amended |
---|
80 | 80 | | to read as follows: |
---|
81 | 81 | | (c) In adopting rules under this section, the commissioner |
---|
82 | 82 | | may only designate [shall consider the standards, guidelines, and |
---|
83 | 83 | | measures prescribed by nationally recognized] organizations that |
---|
84 | 84 | | meet the following requirements: |
---|
85 | 85 | | (1) the prescribing organization is bona fide and |
---|
86 | 86 | | unbiased toward or against any medical provider; |
---|
87 | 87 | | (2) the standards to be used in rankings, comparisons, |
---|
88 | 88 | | or evaluations: |
---|
89 | 89 | | (A) are nationally recognized, or based on |
---|
90 | 90 | | expert-provider consensus or leading clinical evidence-based |
---|
91 | 91 | | scholarship; |
---|
92 | 92 | | (B) have a publicly transparent methodology; and |
---|
93 | 93 | | (C) if based on clinical outcomes, are |
---|
94 | 94 | | risk-adjusted; and |
---|
95 | 95 | | (3) the prescribing organization has an easy-to-use |
---|
96 | 96 | | process by which a medical provider may report data, evidentiary, |
---|
97 | 97 | | factual, or mathematical errors for prompt investigation and, if |
---|
98 | 98 | | appropriate, correction [establish or promote guidelines and |
---|
99 | 99 | | performance measures emphasizing quality of health care, including |
---|
100 | 100 | | the National Quality Forum and the AQA Alliance. If neither the |
---|
101 | 101 | | National Quality Forum nor the AQA Alliance has established |
---|
102 | 102 | | standards or guidelines regarding an issue, the commissioner shall |
---|
103 | 103 | | consider the standards, guidelines, and measures prescribed by the |
---|
104 | 104 | | National Committee on Quality Assurance and other similar national |
---|
105 | 105 | | organizations. If neither the National Quality Forum, nor the AQA |
---|
106 | 106 | | Alliance, nor other national organizations have established |
---|
107 | 107 | | standards or guidelines regarding an issue, the commissioner shall |
---|
108 | 108 | | consider standards, guidelines, and measures based on other bona |
---|
109 | 109 | | fide nationally recognized guidelines, expert-based physician |
---|
110 | 110 | | consensus quality standards, or leading objective clinical |
---|
111 | 111 | | evidence and scholarship]. |
---|
112 | 112 | | SECTION 3. This Act takes effect immediately if it receives |
---|
113 | 113 | | a vote of two-thirds of all the members elected to each house, as |
---|
114 | 114 | | provided by Section 39, Article III, Texas Constitution. If this |
---|
115 | 115 | | Act does not receive the vote necessary for immediate effect, this |
---|
116 | 116 | | Act takes effect September 1, 2023. |
---|